GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » Volatility

Outlook Therapeutics (Outlook Therapeutics) Volatility : 210.56% (As of May. 03, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-05-03), Outlook Therapeutics's Volatility is 210.56%.


Competitive Comparison of Outlook Therapeutics's Volatility

For the Biotechnology subindustry, Outlook Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Volatility falls into.



Outlook Therapeutics  (NAS:OTLK) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Outlook Therapeutics  (NAS:OTLK) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Outlook Therapeutics Volatility Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics (Outlook Therapeutics) Business Description

Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
Executives
Terry Dagnon officer: Chief Operating Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Jeff Evanson officer: Chief Commercial Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin director ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Faisal Ghiath Sukhtian director 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger director 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii director, officer: CEO and President 1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian director, 10 percent owner 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Lawrence A Kenyon officer: CFO and Secretary C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Syntone Ventures Llc 10 percent owner 1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang director C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth director C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments director C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007

Outlook Therapeutics (Outlook Therapeutics) Headlines

From GuruFocus